Haisco Pharmaceutical Group stock
002653.SZSHZHaisco Pharmaceutical Group Co., Ltd., HealthcareISIN CNE100001BC7
68Score 68 out of 100, Neutral
Price and trend
65 / 100
Price history
+8.4% in one yearThe chart shows daily closes over 15 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 1.9% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 26% below its 52-week high. Largest decline in 15 years: 76% (June 2015 to February 2018).
Chart figures for advanced users
- SMA 50$9.21
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$8.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.44
- The lowest closing price of the last twelve months.
- Resistance$11.87
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Haisco Pharmaceutical Group Co., Ltd. belongs to the Biotechnology industry (China) and, with a market value of $10.07B, is number 40 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $651.56M (up 16.8% year on year) and earnings of $38.91M (down 34.4%).
- MEQIRI Score 68 out of 100 (Neutral): rank 166 of 714 in Healthcare, median 53.
Show more
- The P/E is 49.4 (Biotechnology median 46.6, own median of recent years 48.3).
- Our model puts fair value at $5.04, with the price 72% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 78
- High marginNet margin 22.1% over the last 12 months, Biotechnology median 12.4%.Profitability 89
- More cash than debtCash $412.62M, financial debt $340.09M.Stability 70
Weaknesses
- Margin fallingOperating margin 4%, average of the prior years 13.6% (to 2024).
- Above fair valuePrice 72% above the fair value of $5.04.Valuation 21
- Earnings per share fallingDown 17.5% a year since 2020.Growth 69
Its standout strengths are profitability and fundamentals, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $3.60 and expensive above $8.40 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $1.75 (cash-flow model) and $8.33 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.7%. At 9.7% the fair value would be $4.93, at 7.7% it would be $5.20.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (46.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 41.9% on the twelve months before. Revenue has grown strongly since 2008, at around 16% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 69%, operating 4%, net 6%. Last 12 months: net 22%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 21 Apr 2027in 160 days
- Last reported
- 27 Oct 2026EPS reported $0.07 (expected $0.06)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 10.3% since 24 Oct 2026.
- Earnings per share
- $0.22+29.8%
- Revenue
- $1.05B+6.2%
- Earnings per share
- $0.17+10.3%
- Revenue
- $1.05B0.0%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Haisco Pharmaceutical Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Sichuan Kelun Pharmaceutical002422.SZ $10.43B70
- Spyre TherapeuticsSYRE $10.14B48
- TG TherapeuticsTGTX $10.07B65
- Genscript Biotech1548.HK $9.96B48
- Praxis Precision MedicinesPRAX $9.67B42
- Alteogen196170.KQ $9.56B57
- Krystal BiotechKRYS $9.15B66
- Protagonist TherapeuticsPTGX $8.73B68
ETFs that hold Haisco Pharmaceutical Group
Held by 31 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Market Access Stoxx China A Minimum Variance Index UCITS ETFM9SV | 0.76% | 0.45% | €288.53M |
| Amundi MSCI China A UCITS ETF AccCNAA | 0.12% | 0.35% | €83.52M |
| HSBC MSCI China UCITS ETFH4ZP | 0.02% | 0.28% | €865.21M |
Show 5 more
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.3B |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.01% | 0.30% | €134.65M |
| iShares MSCI EM UCITS ETF USD (Dist)IQQE | 0.01% | 0.18% | €8.33B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.01% | 0.18% | €37.17B |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.01% | 0.17% | €5.24B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.